International Journal of Molecular Medical Science, 2025, Vol.15, No.5, 224-234 http://medscipublisher.com/index.php/ijmms 2 32 Conflict of Interest Disclosure The author affirms that this research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest. References Aburaki R., Fujiwara Y., Chida K., Horita N., and Nagasaka M., 2024, Surgical and safety outcomes in patients with non-small cell lung cancer receiving neoadjuvant chemoimmunotherapy versus chemotherapy alone: a systematic review and meta-analysis, Cancer Treatment Reviews, 131: 102833. https://doi.org/10.1016/j.ctrv.2024.102833 Ahmed A., and Tait S., 2020, Targeting immunogenic cell death in cancer, Molecular Oncology, 14: 2994-3006. https://doi.org/10.1002/1878-0261.12851 Akers K., Oskar S., Zhao B., Frederickson A., and Arunachalam A., 2023, Clinical outcomes of PD-1/PD-L1 Inhibitors Among Patients with Advanced or Metastatic Non-Small Cell Lung Cancer with BRAF ERBB2/HER2 MET or RET Alterations: A Systematic Literature Review, Journal of Immunotherapy, 47: 128-138. https://doi.org/10.1097/cji.0000000000000500 Cai S., Zhao M., Yang G., Li C., Hu M., Yang L., Xing L., and Sun X., 2024, Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients, International Immunopharmacology, 137: 112434. https://doi.org/10.1016/j.intimp.2024.112434 Chen L., Xie J., Zhu M., Wang D., Liu H., Zhan P., Yin J., Ye M., Song Y., and LüT., 2024, The safety and efficacy of anti-PD-1 inhibitor-based combinational therapy in non-small cell lung cancer patients with oncogenic alterations, Translational Cancer Research, 13: 137-149. https://doi.org/10.21037/tcr-23-1092 Chen Y., Shi Y., Ding H., Feng Y., Zhang T., Liang Y., Wang H., Song X., Chen B., Xia W., Mao Q., Shen B., Xu L., Dong G., and Jiang F., 2023, Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy, Therapeutic Advances in Medical Oncology, 15: 17588359231210678. https://doi.org/10.1177/17588359231210678 Faghmous I., Nicoale A., Hari P., and Ramsingh G., 2025, Tumor proportion score (TPS) and response to first-line (1L) anti-PD-1/PD-L1 plus chemotherapy for metastatic non-small cell lung cancer (NSCLC): a real-world cohort study, Journal of Clinical Oncology, (2025): e20606. https://doi.org/10.1200/jco.2025.43.16_suppl.e20606 Flieswasser T., Van Den Eynde A., Boullosa L., Melis J., Hermans C., Merlin C., Lau H., Van Audenaerde J., Lardon F., Smits E., Pauwels P., and Jacobs J., 2023, Targeting CD70 in combination with chemotherapy to enhance the anti-tumor immune effects in non-small cell lung cancer, Oncoimmunology, 12(1): 2192100. https://doi.org/10.1080/2162402x.2023.2192100 Flieswasser T., Van Loenhout J., Boullosa L., Van Den Eynde A., De Waele J., Van Audenaerde J., Lardon F., Smits E., Pauwels P., and Jacobs J., 2020, Clinically relevant chemotherapeutics have the ability to induce immunogenic cell death in non-small cell lung cancer, Cells, 9(6): 1474. https://doi.org/10.3390/cells9061474 Fu J., Yan Y., Wan X., Sun X., Ma X., and Su Y., 2025, A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer, Frontiers in Pharmacology, 15: 1516735. https://doi.org/10.3389/fphar.2024.1516735 Grant M., Herbst R., and Goldberg S., 2021, Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC, Nature Reviews Clinical Oncology, 18: 625-644. https://doi.org/10.1038/s41571-021-00520-1 Gu X., Liu Y., Hu Y., Jiang Y., and Zhang Z., 2023, Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review, Frontiers in Pharmacology, 14: 1152934. https://doi.org/10.3389/fphar.2023.1152934 Hoffner B., Leighl N., and Davies M., 2020, Toxicity management with combination chemotherapy and programmed death 1/programmed death ligand 1 inhibitor therapy in advanced lung cancer, Cancer Treatment Reviews, 85: 101979. https://doi.org/10.1016/j.ctrv.2020.101979 Hong W., Xue M., Jiang J., Zhang Y., and Gao X., 2020, Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth stemness drug resistance and immune evasion in non-small cell lung cancer (NSCLC), Journal of Experimental and Clinical Cancer Research, 39(1): 149. https://doi.org/10.1186/s13046-020-01648-1 Huo G., Liu W., and Chen P., 2022, Inhibitors of PD-1 in non-small cell lung cancer: a meta-analysis of clinical and molecular features, Frontiers in Immunology, 13: 875093. https://doi.org/10.3389/fimmu.2022.875093 Jeon H., Wang S., Song J., Gill H., and Cheng H., 2025, Update 2025: management of non-small-cell lung cancer, Lung, 203(1): 53. https://doi.org/10.1007/s00408-025-00801-x Jiang J., Wang Y., Gao Y., Sugimura H., Minervini F., Uchino J., Halmos B., Yendamuri S., Velotta J., and Li M., 2021, Neoadjuvant immunotherapy or chemoimmunotherapy in non-small cell lung cancer: a systematic review and meta-analysis, Translational Lung Cancer Research, 11: 277-294. https://doi.org/10.21037/tlcr-22-75
RkJQdWJsaXNoZXIy MjQ4ODYzNA==